Sign In
Buy VTRS
$15.38
+0.0100 (+0.0651%)
At Close: Jun 22, 2026
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
12:50pm, Friday, 05'th Jun 2026
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
Here's Why Viatris (VTRS) is a Strong Value Stock
10:41am, Thursday, 04'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ISCV Beat IJJ Over the Past Year. Here's Why That Gap Could Easily Reverse.
11:30am, Wednesday, 27'th May 2026
Compare expense ratios, diversification, and risk profiles as these two value-focused ETFs take distinct approaches to portfolio construction.
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
11:17am, Wednesday, 27'th May 2026
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
12:41pm, Tuesday, 19'th May 2026
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
Here's Why Viatris (VTRS) is a Strong Momentum Stock
10:50am, Monday, 18'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
08:00am, Monday, 18'th May 2026
FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
10:40am, Wednesday, 13'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:00pm, Tuesday, 12'th May 2026
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 12'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)
04:54am, Tuesday, 12'th May 2026
Viatris (VTRS) is upgraded to Strong Buy, underpinned by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales CAGR midpoint of 3.5%, exceeding consens
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
12:55pm, Monday, 11'th May 2026
Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effe
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
04:30pm, Thursday, 07'th May 2026
PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Confer
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
02:41pm, Thursday, 07'th May 2026
VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
02:21pm, Thursday, 07'th May 2026
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
